<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">surgonco</journal-id><journal-title-group><journal-title xml:lang="ru">Креативная хирургия и онкология</journal-title><trans-title-group xml:lang="en"><trans-title>Creative surgery and oncology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2076-3093</issn><issn pub-type="epub">2307-0501</issn><publisher><publisher-name>Башкирский государственный медицинский университет</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.24060/2076-3093-2014-0-1-2-17-21</article-id><article-id custom-type="elpub" pub-id-type="custom">surgonco-7</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОПЫТ ЛЕЧЕБНЫХ УЧРЕЖДЕНИЙ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>EXPERIENCE OF HEALTHCARE FACILITIES</subject></subj-group></article-categories><title-group><article-title>ОТДАЛЕННЫЕ РЕЗУЛЬТАТЫ ЛЕЧЕНИЯ ОККУЛЬТНОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ</article-title><trans-title-group xml:lang="en"><trans-title>THE LONG-TERM RESULTS OF OCCULT BREAST CARCINOMA TREATMENT</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кукленко</surname><given-names>Т. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kuklenko</surname><given-names>T. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>врач-онколог маммологического отделения ГБУЗ «ЧОКОД»</p></bio><email xlink:type="simple">kuklek_t@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ГБУЗ Челябинский областной клинический онкологический диспансер</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Regional Oncological Dispensary</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>24</day><month>01</month><year>2017</year></pub-date><volume>0</volume><issue>1-2</issue><fpage>17</fpage><lpage>21</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Кукленко Т.В., 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="ru">Кукленко Т.В.</copyright-holder><copyright-holder xml:lang="en">Kuklenko T.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.surgonco.ru/jour/article/view/7">https://www.surgonco.ru/jour/article/view/7</self-uri><abstract><p>Количество пораженных метастазами лимфоузлов (ЛУ) у больных раком молочной железы (РМЖ) является наиболее важным фактором, предсказывающим выживаемость пациентов. В данной статье приведен ретроспективный и проспективный анализ общей выживаемости, частоты отдаленного метастазирования и локального рецидивирования у 35 пациенток с диагнозом оккультного рака молочной железы (ОРМЖ), представленном подмышечными метастазами TxN1-2M0 (1 группа) и 150 пациентками с пальпируемым раком молочной железы (ПРМЖ) T1-3N1-2M0 с поражением подмышечных ЛУ (2 группа), проходившим лечение в Челябинском областном клиническом онкологическом диспансере за период с 1997 по 2012 гг. Целью работы было сравнение отдаленных результатов лечения больных этих групп для оптимизации лечебно-диагностической тактики при ОРМЖ. В результате исследования было установлено, что общая 5-летняя выживаемость, оцененная методом Каплана-Майера, при ОРМЖ в подгруппе с N2 достоверно ниже, чем при ПРМЖ и составила 46,6% и 63,3% соответственно (р=0,02). Частота отдаленного метастазирования за 5-летний срок наблюдения у больных 1 группы составила 66,6%, а у больных 2 группы - 51,6% (р=0,04) в подгруппе с N2. Различия статистически достоверны. Таким образом, мы доказали более худший прогноз у больных I группы, чем у II-ой в подгруппе с N2, что требует более агрессивной лечебной тактики у данной категории пациенток.</p></abstract><trans-abstract xml:lang="en"><p>In breast cancer patients, axillary status continues to be the most powerful predictor of survival. This article contains retrospective and prospective analysis for 5-year survival, regional and distant recurrences of 35 patients with occult breast cancer (OBC) presenting as isolated axillary nodal metastasis TxN1-2M0 (I group) and 150 cases of node-positive palpable breast cancer (PBC) T1-3N1-2M0 (II group) during the period from 1997 to 2012 according the materials of Chelyabinsk regional oncology dispensary. The aim of this investigation is to compare prognoses of these groups patients after complex treatment to optimistic treating and diagnostic tactic of OBC. Five-year Kaplan-Meier estimate of overall survival among groups of our patients who had had lymph node metastasis status as N2 in I and II group had been allocated as 46,6% and 63,3% respectively (p=0,02). Five-year distant recurrences of disease among groups of our patients who had had lymph node metastasis status as N2 in I and II group had been allocated as 66,6% and 51,6% respectively (p=0,04). The differences observed between patients of these groups were statistically significant. The OBC prognosis is worse than PBC in N2 subgroup that demand more aggressive therapy for patients of I group.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>оккультный рак молочной железы</kwd><kwd>пальпируемый рак молочной железы</kwd><kwd>лимфоузлы</kwd><kwd>подмышечные метастазы</kwd><kwd>прогноз</kwd></kwd-group><kwd-group xml:lang="en"><kwd>occult breast cancer</kwd><kwd>palpable breast cancer</kwd><kwd>lymph node</kwd><kwd>axillary lymph node metastasis</kwd><kwd>prognosis</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Комаров И.Г., Комов Д.В. Метастазы злокачественной опухоли без выявленного первичного очага. - М.: «Триада-Х», 2002. - С. 37-55.</mixed-citation><mixed-citation xml:lang="en">Комаров И.Г., Комов Д.В. Метастазы злокачественной опухоли без выявленного первичного очага. - М.: «Триада-Х», 2002. - С. 37-55.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Blanchard D. Retrospective study of women presenting with axillary metastases from occult breast carcinoma / D. Blanchard, D. Farley // World J. Surg. - 2004. - Vol. 28. - P. 535-539.</mixed-citation><mixed-citation xml:lang="en">Blanchard D. Retrospective study of women presenting with axillary metastases from occult breast carcinoma / D. Blanchard, D. Farley // World J. Surg. - 2004. - Vol. 28. - P. 535-539.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Presentation of axillary lymphadenopathy without detectable breast primary (T0N1b breast cancer): experience at Institut Curie / F. Campana, A. Fourguet, M. Ashby et al. // Radiother Oncol. -1989. - Vol. 15. - P. 321-325.</mixed-citation><mixed-citation xml:lang="en">Presentation of axillary lymphadenopathy without detectable breast primary (T0N1b breast cancer): experience at Institut Curie / F. Campana, A. Fourguet, M. Ashby et al. // Radiother Oncol. -1989. - Vol. 15. - P. 321-325.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Foroudi F. Occult breast carcinoma presenting as axillary metastases / F. Foroudi, K.W. Tiver // Int. J. Radiat. Oncol. Biol. Phys. - 2000. - Vol. 47. - P. 143-147.</mixed-citation><mixed-citation xml:lang="en">Foroudi F. Occult breast carcinoma presenting as axillary metastases / F. Foroudi, K.W. Tiver // Int. J. Radiat. Oncol. Biol. Phys. - 2000. - Vol. 47. - P. 143-147.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Clinical experience with axillary presentation breast cancer / V. Galimberti, G. Bassani, S. Monti et al. // Breast Cancer Res. Treat. - 2004. Vol. 88. - P. 43-47.</mixed-citation><mixed-citation xml:lang="en">Clinical experience with axillary presentation breast cancer / V. Galimberti, G. Bassani, S. Monti et al. // Breast Cancer Res. Treat. - 2004. Vol. 88. - P. 43-47.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Hainsworth J. Management of patients with cancer of unknown primary site / J. Hainsworth, F. Greco // Oncology. 2000. Vol. 14. P. 563-579.</mixed-citation><mixed-citation xml:lang="en">Hainsworth J. Management of patients with cancer of unknown primary site / J. Hainsworth, F. Greco // Oncology. 2000. Vol. 14. P. 563-579.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Clinicopathological characteristics of nonpalpable breast cancer presenting as axillary mass / T. Kyokane, S. Akashi-Tanaka, T. Matsui et al. // Breast Cancer. – 1995. - Vol. 2. - №2. - P. 105-112.</mixed-citation><mixed-citation xml:lang="en">Clinicopathological characteristics of nonpalpable breast cancer presenting as axillary mass / T. Kyokane, S. Akashi-Tanaka, T. Matsui et al. // Breast Cancer. – 1995. - Vol. 2. - №2. - P. 105-112.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Cancer of unknown primary: changing approaches. A multidisciplinary case presentation from the Toan Karnell center of Pennsylvania Hospital / D. Mintzer, M. Warhol, A. Martin et al. // The Oncologist. - 2004. - Vol.</mixed-citation><mixed-citation xml:lang="en">Cancer of unknown primary: changing approaches. A multidisciplinary case presentation from the Toan Karnell center of Pennsylvania Hospital / D. Mintzer, M. Warhol, A. Martin et al. // The Oncologist. - 2004. - Vol.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">- №3. - P. 330-338. 9. Occult primary breast carcinoma presenting as axillary lymphadenopathy / C. Shannon, G. Walsh, F. Sapunar et al. // Breast. 2002. - Vol. 11. - P. 414-418.</mixed-citation><mixed-citation xml:lang="en">- №3. - P. 330-338. 9. Occult primary breast carcinoma presenting as axillary lymphadenopathy / C. Shannon, G. Walsh, F. Sapunar et al. // Breast. 2002. - Vol. 11. - P. 414-418.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Prognosis of occult breast carcinoma presenting as isolated axillary nodal metastasis / R. Varadarjan, S. Edge, J. Yu et al. // Oncology. - 2006. - Vol. 71. - P. 456-459. 11. Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases / G. Vlastos, M. T</mixed-citation><mixed-citation xml:lang="en">Prognosis of occult breast carcinoma presenting as isolated axillary nodal metastasis / R. Varadarjan, S. Edge, J. Yu et al. // Oncology. - 2006. - Vol. 71. - P. 456-459. 11. Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases / G. Vlastos, M. T</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">ean, A. Mizza et al. // Ann. Surg. Oncol. - 2001. - Vol. 8. - P. 425-431.</mixed-citation><mixed-citation xml:lang="en">ean, A. Mizza et al. // Ann. Surg. Oncol. - 2001. - Vol. 8. - P. 425-431.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Population-based analysis of occult primary breast cancer with axillary lymph node metastasis / G. Walker, G. Smith, G. Perkins et al. // Cancer. 2010. - Vol. 116. - P. 4006-4006.</mixed-citation><mixed-citation xml:lang="en">Population-based analysis of occult primary breast cancer with axillary lymph node metastasis / G. Walker, G. Smith, G. Perkins et al. // Cancer. 2010. - Vol. 116. - P. 4006-4006.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
